Market Research & Insights
Achieving launch excellence in orphan medicines
New rare disease treatments face a complex market access landscape that presents fundamental challenges for pharmaceutical companies seeking to achieve launch excellence.
Each rare disease might only affect a small percentage of the population, but orphan medicines are growing in interest and importance for pharmaceutical companies, increasing the pressure to make each product launch as successful as possible.
A new frontier of challenge faces Orphan Medicines companies as the gap between Orphan Medicines and mainstream specialty products narrows.
To assess the market access environment for orphan medicines, and launch excellence strategies that manufacturers can employ, a recent IQVIA report examined some of the challenges that pharma companies face.
News & Trends - MedTech & Diagnostics
Roche Diagnostics MD bids farewell after two-decades, leading the organisation to new heights of success
Diagnostics & MedTech News: The Managing Director of Roche Diagnostics Australia, Allison Rossiter, has announced her resignation, effective September 2024. […]
MoreNews & Trends - Pharmaceuticals
Is Australia ready to play a leading role in precision nuclear medicines?
Pharma News: A newly released discussion paper unveils Australia’s preparedness to take the helm in the rise of the global […]
MoreNews & Trends - MedTech & Diagnostics
Minimally invasive procedure a first in epilepsy treatment
MedTech & Diagnostics News: A new MRI guided and minimally invasive surgery has marked an Australian-first procedure for the treatment […]
MoreNews & Trends - Pharmaceuticals
Stakeholders unite in international call to tackle breast cancer gaps and inequities
Pharma News: Breast Cancer Network Australia (BCNA) has united in an international call to raise breast cancer care standards and […]
More